LY-503,430

LY-503,430
(IUPAC) ime
	4'- {(1S)-1-fluoro-2-[(izopropilsulfonil)amino]-1-metiletil} -N-metilbifenil-4-karboksamid
Klinički podaci
Identifikatori
CAS broj	625820-83-9
ATC kod	nije dodeljen
ChemSpider	21212986
Hemijski podaci
Formula	C20H25FN2O3S
Mol. masa	392,49 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C20H25FN2O3S/c1-14(2)27(25,26)23-13-20(3,21)18-11-9-16(10-12-18)15-5-7-17(8-6-15)19(24)22-4/h5-12,14,23H,13H2,1-4H3,(H,22,24) ; Key: MFJKNXILEXBWNQ-UHFFFAOYSA-N
Sinonimi	LY-503,430; (R)-4'-[1-fluoro-1-methyl-2-(propane-2-sulfonylamino)-ethyl]-biphenyl-4-carboxylic acid methylamide
Farmakoinformacioni podaci
Trudnoća	?
Pravni status	Lek u razvoju
Način primene	oralno

LY-503,430 je ampakinski lek koji je razvila kompanija Eli Lili.^[2]

LY-503,430 proizvodi nootropne i neuroprotektivne efekte, čime redukuje moždana oštećenja uzrokovana 6-hidroksidopaminom ili MPTP-om. On isto tako povišava nivoe neurotrofnog faktora BDNF u mozgu, posebno u substantia nigra, hipokampusu i striatumu.^[3]^[4] On je oralno aktivan. LY-503,430 se razvija za moguću primenu u lečenju Parkinsonove bolesti. Moguće je će naći primenu i u tretmanju Alchajmerove bolesti, depresije i šizofrenije.^[5]^[6]

Reference

↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
↑ O'neill, MJ; Murray, TK; Clay, MP; Lindstrom, T; Yang, CR; Nisenbaum, ES (2005). „LY503430: pharmacology, pharmacokinetics, and effects in rodent models of Parkinson's disease”. CNS Drug Reviews 11 (1): 77–96. DOI:10.1111/j.1527-3458.2005.tb00037.x. PMID 15867954.
↑ Murray, TK; Whalley, K; Robinson, CS; Ward, MA; Hicks, CA; Lodge, D; Vandergriff, JL; Baumbarger, P et al (2003). „LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease”. The Journal of Pharmacology and Experimental Therapeutics 306 (2): 752–62. DOI:10.1124/jpet.103.049445. PMID 12730350.
↑ Ryder, JW; Falcone, JF; Manro, JR; Svensson, KA; Merchant, KM (2006). „Pharmacological characterization of cGMP regulation by the biarylpropylsulfonamide class of positive, allosteric modulators of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors”. The Journal of Pharmacology and Experimental Therapeutics 319 (1): 293–8. DOI:10.1124/jpet.106.105734. PMID 16803862.
↑ O'neill, MJ; Bleakman, D; Zimmerman, DM; Nisenbaum, ES (2004). „AMPA receptor potentiators for the treatment of CNS disorders”. Current drug targets. CNS and neurological disorders 3 (3): 181–94. DOI:10.2174/1568007043337508. PMID 15180479.
↑ O'neill, MJ; Witkin, JM (2007). „AMPA receptor potentiators: application for depression and Parkinson's disease”. Current drug targets 8 (5): 603–20. DOI:10.2174/138945007780618517. PMID 17504104.

Vanjske veze

	Portal Medicina
	Portal Hemija

[1] Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit

[2] O'neill, MJ; Murray, TK; Clay, MP; Lindstrom, T; Yang, CR; Nisenbaum, ES (2005). „LY503430: pharmacology, pharmacokinetics, and effects in rodent models of Parkinson's disease”. CNS Drug Reviews 11 (1): 77–96. DOI:10.1111/j.1527-3458.2005.tb00037.x. PMID 15867954.

[3] Murray, TK; Whalley, K; Robinson, CS; Ward, MA; Hicks, CA; Lodge, D; Vandergriff, JL; Baumbarger, P et al (2003). „LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease”. The Journal of Pharmacology and Experimental Therapeutics 306 (2): 752–62. DOI:10.1124/jpet.103.049445. PMID 12730350.

[4] Ryder, JW; Falcone, JF; Manro, JR; Svensson, KA; Merchant, KM (2006). „Pharmacological characterization of cGMP regulation by the biarylpropylsulfonamide class of positive, allosteric modulators of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors”. The Journal of Pharmacology and Experimental Therapeutics 319 (1): 293–8. DOI:10.1124/jpet.106.105734. PMID 16803862.

[5] O'neill, MJ; Bleakman, D; Zimmerman, DM; Nisenbaum, ES (2004). „AMPA receptor potentiators for the treatment of CNS disorders”. Current drug targets. CNS and neurological disorders 3 (3): 181–94. DOI:10.2174/1568007043337508. PMID 15180479.

[6] O'neill, MJ; Witkin, JM (2007). „AMPA receptor potentiators: application for depression and Parkinson's disease”. Current drug targets 8 (5): 603–20. DOI:10.2174/138945007780618517. PMID 17504104.

[1]

[2]

[3]

[4]

[5]

[6]